Chapter 21 The liver in pregnancy
1 Liver diseases in pregnancy include those that occur exclusively in pregnancy and those that occur coincidentally in pregnancy or are present at the time of pregnancy.
2 Normal physiologic changes in pregnancy may alter the normal range for liver biochemical tests (Table 21.1).
4 Laboratory findings with particular importance to diagnosing liver disease in pregnancy are proteinuria, hyperuricemia, elevated serum bile acid levels, thrombocytopenia, and anemia.
5 Abdominal ultrasonography may be helpful. Liver biopsy is rarely necessary, but it may be diagnostic for acute fatty liver of pregnancy.
6 Timely diagnosis and hence appropriate treatment are critical to outcome. Delivery of the infant is indicated for severe pre-eclampsia, eclampsia, acute fatty liver of pregnancy, and HELLP (hemolysis, elevated liver tests, low platelets) syndrome, and immunization is indicated in infants born to mothers with hepatitis B.
7 Although women with chronic liver disease may have more trouble conceiving, pregnancy has no adverse effect on the progression of liver disease.
Test | Change | Trimester of maximum change |
---|---|---|
Albumin | ↓ 10%–60% | Second |
Gamma globulins | None to slight ↓ | Third |
Fibrinogen | ↓ 50% | Second |
Transferrin | ↓ | Third |
Bilirubin | None | — |
Alkaline phosphatase | ↓ Two- to fourfold | Third |
AST | None | — |
ALT | None | — |
Cholesterol | ↓ Twofold | Third |
↓, increase; ↓, decrease; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
From Olans LB, Wolf JL. Liver disease in pregnancy. In: Carlson KJ, Eisenstat SA, eds. The Primary Care of Women, 2nd edn. St. Louis: Mosby–Year Book; 2003:531–539.
Overview
2. The approach to the pregnant patient with abnormal liver biochemical test levels should include thorough history taking and physical examination.
Approach to the Pregnant Patient
History
6. Systemic symptoms
Headache, peripheral edema, foamy urine, oliguria, and neurologic symptoms may occur in pre-eclampsia
Trimester | Differential diagnosis |
---|---|
First | Hyperemesis gravidarum |
Gallstones | |
Viral hepatitis | |
Drug-induced hepatitis | |
Intrahepatic cholestasis of pregnancy∗ | |
Second | Intrahepatic cholestasis of pregnancy |
Gallstones | |
Viral hepatitis | |
Drug-induced hepatitis | |
Pre-eclampsia/eclampsia∗ | |
HELLP syndrome∗ | |
Third | Intrahepatic cholestasis of pregnancy |
Pre-eclampsia/eclampsia | |
HELLP syndrome | |
Acute fatty liver of pregnancy | |
HELLP, hemolysis, elevated liver tests, low platelets.
From Olans LB, Wolf J. Liver disease in pregnancy. In: Carlson KJ, Eisenstat SA, eds. The Primary Care of Women, 2nd edn. St. Louis: Mosby–Year Book; 2003:531–539.
Disease | Rate of recurrence |
---|---|
Intrahepatic cholestasis of pregnancy | 40%–70% |
HELLP syndrome | 4%–27% |
Acute fatty liver of pregnancy | 20%–70% in carriers of LCHAD mutation |
Pre-eclampsia | 2%–43% |
HELLP, hemolysis, elevated liver tests, low platelets; LCHAD, long-chain 3-hydroxyacyl-coenzyme A dehydrogenase.
Physical examination
Abnormal findings that occur with liver disease in pregnancy are jaundice, hepatomegaly, hepatic tenderness, friction rub or bruit, splenomegaly, Murphy’s sign, and diffuse excoriations
Diagnostic tests
The only major restrictions compared with the nongravid state are radiation and gadolinium exposures
Routine blood chemistry tests and a blood count are helpful. Uric acid levels are often elevated in AFLP and may be elevated in pre-eclampsia
Hemolysis and a low platelet count occur in HELLP syndrome. Disseminated intravascular coagulation (DIC) with a low fibrinogen level, increased fibrin split products, and an elevated partial thromboplastin time may also occur in HELLP syndrome
If viral hepatitis is suspected, serologic tests should be checked for the following: hepatitis A (immunoglobulin M [IgM] and IgG antibody to hepatitis A virus [anti-HAV]); hepatitis B (surface antigen [HBsAg] and antibody, core antibody, and, if HBsAg is positive, e antigen and antibody); hepatitis C (antibody to hepatitis C virus [anti-HCV] and possibly HCV RNA). If the patient has traveled to an endemic area, consider testing for hepatitis E (see Chapter 3)
The benefits of endoscopy, including endoscopic retrograde cholangiopancreatography (ERCP), should be weighed against the risks in pregnancy. Risks include fetal hypoxia from sedative drugs or positioning. Sedative medications and radiation exposure should be minimized
Although abdominal computed tomography (CT) is more sensitive than abdominal ultrasonography for hepatic rupture and may yield more information, radiation exposure and the stability of the patient should be considered in decisions about the choice of imaging test
Liver Disorders Unique to Pregnancy
See Table 21.4 for the laboratory findings associated with these disorders.
Hyperemesis gravidarum
1. Definition: Intractable vomiting in pregnancy that leads to dehydration, electrolyte disturbances, weight loss of 5% or more, and nutritional deficiencies.
3. Etiology: Thought to be multifactorial involving immunologic, hormonal, and psychological factors.
4. Clinical and laboratory features
Serum alanine aminotransferase (ALT) elevations generally 1- to 3-fold but may reach 20 times the upper limit of normal
6. Treatment: Supportive with rehydration, vitamin supplementation, small and frequent low-fat meals, and antiemetics (e.g., metoclopramide 10 to 30 mg orally four times daily or 10 mg intramuscularly or intravenously every 4 to 6 hours or ondansetron 4 to 8 mg orally every 8 hours or 8 mg intravenously every 4 to 8 hours); total parenteral nutrition possibly needed in severe cases.
Intrahepatic cholestasis of pregnancy
1. Definition: Reversible form of cholestasis characterized by intense pruritus in pregnancy, elevated serum ALT and fasting serum bile acid levels, and spontaneous relief of symptoms and signs within 4 to 6 weeks after delivery.
2. Epidemiology
Incidence: 0.01% to 2%, with higher incidence in South Asian, South American, and Scandinavian populations; highest incidence (up to 27%) in Chilean Araucanian Indians
3. Etiology: Multifactorial, including genetic, hormonal, and environmental factors. Theories include the following:
Gene variants of hepatocanalicular transport proteins (ATP-binding cassette [ABC] transporter B4 = phosphatidylcholine floppase, ABC transporter B11 = bile salt export pump, ABC transporter C2 = conjugated organic anion transporter, ATP8B1 = FIC1) and their regulators (e.g., the bile acid sensor farnesoid X receptor, FXR) found in some patients; incidence of IHCP increased in mothers of children with progressive familial intrahepatic cholestasis (PFIC) type 3
4. Clinical and laboratory features
Elevated serum aminotransferase levels (up to four-fold), serum bile acid levels (30–100x), mono- or disulfated progesterone metabolites (particularly 3- and 5-alpha isomers), and occasionally serum cholesterol and triglyceride levels